Antisense therapy restores fragile X protein production in human cells
Science Daily: Pharmacology News
JULY 5, 2023
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Science Daily: Pharmacology News
JULY 5, 2023
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.
Broad Institute
JULY 19, 2024
A new study reveals that C1q can also enter neurons, where it influences protein production, and can accumulate within neurons over time. They also suggest that C1q influences learning, memory, and flexibility in the adult brain, potentially by interacting with specific complexes within neurons that impact protein production.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
APRIL 5, 2024
Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. Skilled CDMOs can also locate or create favourable genomic microenvironments where transcription factors are efficiently recruited, further boosting protein production.
Broad Institute
MARCH 22, 2024
Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic protein production in cells and animals.
Broad Institute
MAY 14, 2024
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology awarded to F.
SCIENMAG: Medicine & Health
JULY 13, 2023
Transfer RNAs (tRNAs) are among the most common types of RNA in a cell and are indispensable for protein production in all known organisms.
BioPharma Drive: Drug Pricing
JANUARY 29, 2024
A successor medicine to Sarepta's Exondys 51 appeared better at boosting dystrophin protein production, but was associated with electrolyte imbalances.
Chemical Biology and Drug Design
AUGUST 23, 2023
We hypothesized that ligustrazine could protect liver by decreasing the inflammation response, protein production, and apoptosis in THS rats. The protein expressions were detected via western blot. It also decreases the platelets' bioactivity and reduces reactive oxygen species formation.
Broad Institute
JUNE 29, 2023
They found key differences between where mRNAs are made and where the corresponding proteins are being translated in several cell types, suggesting that cells are regulating translation in ways that existing transcriptomic methods, which analyze mRNA production, aren’t able to detect. By Sarah C.P. and Virginia W.
Drug Target Review
OCTOBER 10, 2023
The focus of this new centre will be on the development and production of research- and diagnostic-grade proteins and antibodies utilising mammalian cells, which possess the unique machinery to yield natural, in vivo -like products with high bioactivity,” stated Dr Rob Burgess, Chief Business Officer for Sino Biological.
Drug Target Review
MARCH 15, 2024
Advancements in cell line development (CLD), including screening and selection of final clones, scale up, automation and digitalisation have enabled precision and enhanced productivity. Efforts have focused on Chinese hamster ovary (CHO) cell line improvements since it is a commonly used host for the expression of therapeutic proteins.
FDA Law Blog: Biosimilars
JULY 11, 2023
Koblitz — One of the most important questions FDA has to answer is whether a given product is appropriately characterized as a drug, biologic, device, food, cosmetic, or something entirely different. As we have explained before , that distinction is critical to assigning a particular product to the appropriate regulatory scheme.
FDA Law Blog: Biosimilars
MARCH 5, 2024
Gaulkin & Riëtte van Laack — As readers of this blog know, there is a lot of contention about the naming of alternative protein products (APPs), including both plant-based and cell-cultured alternatives for (traditional) animal products. We’ve previously blogged about this ongoing battle here , here , here , and here.
Agency IQ
APRIL 12, 2024
Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?
The Pharma Data
JANUARY 16, 2021
Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.
Drug Target Review
JULY 5, 2023
A good introduction to the use of CHO cells for biotherapeutics production can be found in an article commemorating the 20th anniversary of the approval of a product produced using CHO cells. Over time, there may also be a cost benefit with developing a proprietary system if there is a pipeline of multiple products to produce.
Codon
MARCH 24, 2024
The market for semaglutide-based products is projected to swell to $71B in less than a decade. All of this future value, of course, relies upon these companies actually making enough of their product to meet the growing demand. In November, Novo Nordisk invested $6B in additional production capacity.
Sygnature Discovery
SEPTEMBER 12, 2024
Protein Purification Standard chromatography methods for purification of high grade protein. In vivo biotinylation of target protein. Dedicated Membrane protein production team. Protein refolding from inclusion bodies. Low endotoxin batches. Low endotoxin batches.
Sygnature Discovery
SEPTEMBER 11, 2024
We’ve successfully tackled targets for: Unprecedented membrane proteins Intrinsically disordered proteins Refolding from inclusion bodies Large protein complexes Labelled proteins for NMR studies RNA structures by crystallography Across our capabilities Protein Expression & Purification Vast diversity of proteins produced.
Sygnature Discovery
APRIL 26, 2022
Sygnature have acquired Peak Proteins Ltd. Following an extensive partnership between the two companies, this deal will enable seamless integration of protein production and related structure determination projects within Sygnature. The Peak Proteins leadership team will also remain with the business.
Sygnature Discovery
SEPTEMBER 12, 2024
High quality protein production in-house Protein quality is the key factor for structure projects. We have extensive experience in producing difficult proteins, including membrane proteins. PANDDA analysis for rapid delivery of a hit list. Fragment analogs identified for rapid follow-up.
The Pharma Data
OCTOBER 14, 2020
Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases.
Drug Target Review
NOVEMBER 1, 2023
We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. With all these diverse methods we characterise protein-ligand interactions in many ways.
The Pharma Data
OCTOBER 18, 2021
Tofersen binds to SOD1 mRNA, allowing for its declination by RNase-H in an trouble to reduce conflation of SOD1 protein product. About Tofersen Tofersen is an antisense medicine being estimated for the implicit treatment of SOD1-ALS.
The Pharma Data
DECEMBER 22, 2020
Using the obtained sequencing data, Kao Corporation was able to produce an antibody sample in one week using protein production technology such as enzymes cultivated by our technology. Comment from Fumiharu Muroga, Growth Manager at Real Tech Fund] “Proteins are an important structural component of living things.
The Pharma Data
MARCH 23, 2022
Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral protein production,” says Fang. “The virus hijacks this protein and makes it do something different than its normal job in cells. “We weren’t expecting to see this,” says Fang.
Broad Institute
AUGUST 24, 2022
LIG1 ’s protein product is a critical component of lagging strand DNA synthesis that connects Okazaki fragments (small DNA segments that must be connected to complete the synthesis reaction).
The Pharma Data
JANUARY 24, 2021
Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, humanisation, formats, products and process including over 25 patents granted in the US, Europe and other territories.
Codon
MARCH 20, 2023
Point-of-care peptide hormone production enabled by cell-free protein synthesis. Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast. Optogenetic closed-loop feedback control of the unfolded protein response optimizes protein production. Murakami K. DeWinter MA.
Codon
MAY 30, 2023
Biosynthesis of cannabigerol and cannabigerolic acid, the gateways to further cannabinoid production. Read Maximizing protein production by keeping cells at optimal secretory stress levels using real-time control approaches. He took products to market at prices people were willing to pay. Synthetic Biology. coli cells.
Codon
MAY 30, 2023
Biosynthesis of cannabigerol and cannabigerolic acid, the gateways to further cannabinoid production. Read Maximizing protein production by keeping cells at optimal secretory stress levels using real-time control approaches. He took products to market at prices people were willing to pay. Synthetic Biology. coli cells.
Dark Matter Blog
JULY 16, 2021
At Biogen, my group’s work covered a range of technology development areas including protein production in mammalian cells, intracellular protein delivery (our work on HIV Tat started the field of cell-penetrating peptides) and novel gene delivery vehicles, as well as biological drug discovery and development.
PLOS: DNA Science
JUNE 13, 2024
The most compelling evidence for the origin lies in the RNA genome sequence similarities between RaTG13 and SARS-CoV-2 – specifically, a part that encodes the “furin binding site” of the spike protein with which the virus adheres to host cells. Coincidence? I’ve never thought so.
The Pharma Data
JANUARY 13, 2021
The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. Aker BioMarine will supply the company with all its LPC product needs.
The Pharma Data
DECEMBER 3, 2020
These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning.
Drug Target Review
DECEMBER 10, 2024
Today, I lead an incredible team of engineers, leveraging my natural talents alongside my education in our pursuit of making bio-produced products more accessible. The main challenge right now is cost; we need to find ways to produce these products affordably enough for widespread adoption.
PLOS: DNA Science
AUGUST 8, 2024
Imprinting disorders can also result from differences between parental genders in gene expression – that is, protein production from the encoded information. In Prader-Willi and Angelman syndromes, a tiny section of the same chromosome is absent.
Codon
AUGUST 10, 2023
Link DNA Cost and Productivity Data, aka "Carlson Curves" , by Carlson R. Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Link An integrated cell-free metabolic platform for protein production and synthetic biology , by Jewett M.C. Nature Biotechnology (2009). Nature (2017).
Codon
AUGUST 10, 2023
Link DNA Cost and Productivity Data, aka "Carlson Curves" , by Carlson R. Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Link An integrated cell-free metabolic platform for protein production and synthetic biology , by Jewett M.C. Nature Biotechnology (2009). Nature (2017).
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content